SPRINGWORKS THERAPEUTICS INC (SWTX) Forecast, Price Target & Analyst Ratings
NASDAQ:SWTX • US85205L1070
46.99 USD
+0.01 (+0.02%)
At close: Jun 30, 2025
46.98 USD
-0.01 (-0.02%)
After Hours: 6/30/2025, 8:00:01 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for SPRINGWORKS THERAPEUTICS INC (SWTX).
Forecast Snapshot
Consensus Price Target
$53.33
+ 13.50% Upside
Next Earnings Forecast
Release DateAug 5, 2025
PeriodQ2 / 2025
EPS Estimate-$0.81
Revenue Estimate72.531M
ChartMill Buy Consensus
50.91%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$53.33
Upside
+ 13.50%
From current price of $46.99 to mean target of $53.33, Based on 11 analyst forecasts
Low
$47.47
Median
$47.94
High
$88.20
Price Target Revisions
1 Month
0.00%
3 Months
-28.25%
Price Target Summary
11 analysts have analysed SWTX and the average price target is 53.33 USD. This implies a price increase of 13.5% is expected in the next year compared to the current price of 46.99.
The average price target has been revised downward by 28.25% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
50.91%
SWTX was analyzed by 11 analysts. The buy percentage consensus is at 51. So analysts seem to be rather neutral about SWTX.
In the previous month the buy percentage consensus was at a similar level.
SWTX was analyzed by 11 analysts, which is quite many. So the average rating should be quite meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-05-12 | Guggenheim | Reiterate | Neutral -> Neutral |
| 2025-04-30 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2025-04-29 | TD Cowen | Downgrade | Buy -> Hold |
| 2025-04-29 | Guggenheim | Downgrade | Buy -> Neutral |
| 2025-04-28 | Barclays | Downgrade | Overweight -> Equal-Weight |
| 2025-02-24 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-21 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-12 | Wedbush | Reiterate | Outperform -> Outperform |
| 2025-02-12 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2025-02-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-08 | Guggenheim | Maintains | Buy -> Buy |
| 2024-11-20 | Evercore ISI Group | Initiate | Outperform |
| 2024-11-12 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-09-04 | JP Morgan | Maintains | Overweight -> Overweight |
| 2024-08-28 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-06-04 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-31 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-03-06 | JP Morgan | Maintains | Overweight -> Overweight |
| 2024-03-06 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-02-29 | Barclays | Maintains | Overweight -> Overweight |
| 2024-02-26 | Wedbush | Maintains | Outperform -> Outperform |
| 2024-01-25 | Barclays | Maintains | Overweight -> Overweight |
| 2023-11-29 | Goldman Sachs | Maintains | Buy -> Buy |
| 2023-11-29 | HC Wainwright & Co. | Maintains | Buy -> Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateAug 5, 2025
PeriodQ2 / 2025
EPS Estimate-$0.81
Revenue Estimate72.531M
Revenue Q2Q21.43%
EPS Q2Q-50.54%
Number of Analysts9
Next Earnings Revisions
Revenue (1 Month)
-3.51%
Revenue (3 Months)
-4.74%
EPS (1 Month)
0.00%
EPS (3 Months)
-12.25%
Next Earnings Summary
SWTX is expected to report earnings on 8/5/2025. The consensus EPS estimate for the next earnings is -0.81 USD and the consensus revenue estimate is 72.53M USD.
The next earnings revenue estimate has been revised downward by 4.74% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 5.447M | 191.589M 3,417.33% | 334.05M 74.36% | 586.68M 75.63% | 805.94M 37.37% | 897.75M 11.39% | 1.064B 18.52% | 1.268B 19.17% | 1.441B 13.64% | 1.624B 12.70% | ||
| EBITDA YoY % growth | -279.9M -61.81% | -341.346M -21.95% | -274.663M 19.54% | -183.309M 33.26% | 9.231M 105.04% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -280.67M -61.80% | -343.013M -22.21% | -278.131M 18.92% | -235.648M 15.27% | -116.223M 50.68% | 131.71M 213.32% | 148.26M 12.57% | 76.296M -48.54% | 208.49M 173.26% | 319.26M 53.13% | 439.42M 37.64% | |
| Operating Margin | N/A | -6,297.28% | -145.17% | -70.54% | -19.81% | 16.34% | 16.51% | 7.17% | 16.44% | 22.16% | 27.06% | |
| EPS YoY % growth | -5.21 -45.47% | -5.15 1.11% | -3.48 32.43% | -2.81 19.40% | -1.51 46.26% | 1.21 180.02% | 2.23 84.78% | 1.60 -28.15% | 3.52 119.75% | 5.21 48.12% | 5.51 5.68% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|
| EPS Q2Q % growth | -0.81 -50.54% | -0.68 5.21% | -0.48 54.23% |
| Revenue Q2Q % growth | 72.531M 21.43% | 87.451M 77.38% | 106.79M 73.50% |
| EBITDA Q2Q % growth | -62.22M -43.54% | -40.8M 26.47% | -19.38M 75.11% |
| EBIT Q2Q % growth | -68.301M -52.05% | -57.3M 1.10% | -43.156M 46.94% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
32.89%
EPS Next 5 Year
19.73%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
60.55%
Revenue Next 5 Year
40.44%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
SPRINGWORKS THERAPEUTICS INC / SWTX Forecast FAQ
What do analysts expect the price target to be for SPRINGWORKS THERAPEUTICS INC (SWTX)?
11 analysts have analysed SWTX and the average price target is 53.33 USD. This implies a price increase of 13.5% is expected in the next year compared to the current price of 46.99.
When does SPRINGWORKS THERAPEUTICS INC (SWTX) report earnings?
SPRINGWORKS THERAPEUTICS INC (SWTX) will report earnings on 2025-08-05, before the market open.
Can you provide the consensus estimates for SPRINGWORKS THERAPEUTICS INC next earnings?
The consensus EPS estimate for the next earnings of SPRINGWORKS THERAPEUTICS INC (SWTX) is -0.81 USD and the consensus revenue estimate is 72.53M USD.
How many analysts have analysed SPRINGWORKS THERAPEUTICS INC (SWTX)?
The number of analysts covering SPRINGWORKS THERAPEUTICS INC (SWTX) is 11.